The Barcelonaβeta Dementia Prevention Research Clinic is a pioneering research project that studies the risk, and its biological bases, of developing dementia within 5-years in people with subjective memory complaints. The study was launched in May 2018, lasts 3 years and will incorporate 400 participants between 60 and 80 years old, who are experiencing a decrease in memory or other cognitive abilities, but who have not been diagnosed with Alzheimer's disease or any other form of dementia or disease that could justify it.
The project will offer participants a customized and individualized action plan to reduce their risk. This plan consists of a series of advice aimed at the reduction of modifiable risk factors of the disease, and contemplates the possibility of offering participation in specific studies of detection and prevention of Alzheimer's disease to those people who meet the corresponding criteria.
Participants are visited by a neurologist at the facilities of Barcelonaβeta Brain Research Center, where they are also subjected to cognitive, neuroimaging and genetic tests. Based on the information gathered in these tests, an algorithm is applied that calculates the estimated risk percentage of suffering dementia in the next 5 years.
In addition to investigating if there is a biological basis associated with the calculated risk algorithm, the project also studies the possible emotional impact that the fact of individually revealing this risk percentage may have, as well as the benefits that may be derived from participation in the study. Each participant will have a personalized follow-up that will last a total of 1 year.
Principal Investigator of the Barcelonaβeta Dementia Prevention Research Clinic
José Luis Molinuevo, scientific director of the Alzheimer's Prevention Program.
Molinuevo is co-author of more than 300 scientific articles with more than 15,000 citations in prestigious journals, and a 63 h index. In addition, he participates in networks related to the standardization of procedures and clinical criteria of Alzheimer’s disease, such as the Alzheimer Biomarker Standarization Initiative, the International Working Group, the National Institute on Aging and Alzheimer's Association (NIA-AA) Research framework, the CSF Appropriate Use Criteria Workgroup, the Standardization of CSF Preanalytics Working Group and the Subjective Cognitive Decline Initiative (SCD-I) Working Group.